Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5-11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022.

Autor:	Cortese MM; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Taylor AW; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Akinbami LJ; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Thames-Allen A; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Yousaf AR; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Campbell AP; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Maloney SA; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Harrington TA; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Anyalechi EG; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Munshi D; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Kamidani S; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA., Curtis CR; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., McCormick DW; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Staat MA; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Edwards KM; Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Creech CB; Vanderbilt University Vaccine Research, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Museru O; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Marquez P; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Thompson D; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Su JR; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Schlaudecker EP; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Broder KR; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2023 Jul 14; Vol. 228 (2), pp. 143-148.
DOI:	10.1093/infdis/jiad051
Abstrakt:	Multisystem inflammatory syndrome in children (MIS-C) is a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; in the United States, reporting of MIS-C after coronavirus disease 2019 (COVID-19) vaccination is required for vaccine safety monitoring. Pfizer-BioNTech COVID-19 vaccine was authorized for children aged 5-11 years on 29 October 2021. Covering a period when approximately 7 million children received vaccine, surveillance for MIS-C ≤ 90 days postvaccination using passive systems identified 58 children with MIS-C and laboratory evidence of past/recent SARS-CoV-2 infection, and 4 without evidence. During a period with extensive SARS-CoV-2 circulation, MIS-C illness in children after COVID-19 vaccination who lacked evidence of SARS-CoV-2 infection was rare (<1 per million vaccinated children). Competing Interests: Potential conflicts of interest. S. K.'s institution has received funding from National Institutes of Health (NIH) to conduct clinical trials of Moderna and Janssen COVID-19 vaccines, and funding from Pfizer to conduct clinical trials of Pfizer-BioNTech COVID-19 vaccines. M. A. S. reports funding from NIH, CDC, Pfizer, and Merck; and royalties from UpToDate. K. E. reports grant funding from NIH and CDC; consultant to Bionet, GSK, and IBM; and membership of Data Safety and Monitoring Board for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche. C. B. C. reports grants from NIH and Merck; royalties from UpToDate; consulting fees from GlaxoSmithKline, Horizon Pharma, Premier Healthcare, Pfizer, Moderna, Cowen Investments, and Vindico; payment for medicolegal testimony from multiple firms (none related to this investigation); a US patent for staphylococcal antibody (number 10 981 979); participation on a data safety monitoring board or advisory board for Astellas; and is President of the Pediatric Infectious Diseases Society. E. P. S. reports grants from the NIH and Pfizer; consulting fees from Sanofi Pasteur; and serves on the Data Safety Monitoring Board for vaccine trials sponsored by the NIH's Division of Microbiology and Infectious Diseases. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu